Drug intelligence / Profile preview

INR-301

Development stage: Preclinical
Lead developer: Imnewrun Biosciences
Modality: Antibody-Based Therapeutics

Overview

INR-301 is a novel blood-brain barrier (BBB)-penetrating anti-PD-L1 antibody developed for the treatment of Alzheimer's disease. It functions as an inhibitor of programmed death-ligand 1 (PD-L1), a target implicated in neuroinflammation and immune modulation within the central nervous system. Preclinical studies have demonstrated that INR-301 exhibits superior brain pharmacokinetic properties compared to other antibodies, suggesting enhanced delivery to the brain. The drug is being developed by Imnewrun Biosciences and has reached preclinical development status for Alzheimer's disease[1][8].

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on INR-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INR-301.

Explore the full profile